抜歯後疼痛に対する CS-670 の臨床評価 - 二重盲検法による多施設共同研究 -  [in Japanese] Clinical evaluation of CS-670 in the treatment of postexodontic pain - A multicenter double-blind study -  [in Japanese]

Access this Article

Search this Article

Author(s)

    • 高井 宏 TAKAI Hiroshi
    • 奥羽大学歯学部口腔外科学第一講座 First Department of Oro - Maxillo - Facial Surgery, School of Dentistry, Ohu University
    • 佐藤 田鶴子 SATOH Tazuko
    • 日本歯科大学歯学部口腔外科学教室第一講座 The Nippon Dental University, School of Dentistry at Tokyo, Department of Oral and Maxillofacial Surgery 1
    • 宗村 治 MUNEMURA Osamu
    • 日本歯科大学歯学部口腔外科学教室第一講座 The Nippon Dental University, School of Dentistry at Tokyo, Department of Oral and Maxillofacial Surgery 1
    • 道 健一 MICHI Ken-ichi
    • 昭和大学歯学部第一口腔外科学教室 First Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University
    • 松田 千春 MATSUDA Chiharu
    • 昭和大学歯学部第一口腔外科学教室 First Department of Oral and Maxillofacial Surgery, School of Dentistry, Showa University
    • 瀬戸 晧一 SETO Kan-ichi
    • 鶴見大学歯学部第一口腔外科学教室 First Department of Oral and Maxillofacial Surgery, School of Dentistry, Tsurumi University
    • 松浦 正朗 MATSUURA Masaroh
    • 鶴見大学歯学部第一口腔外科学教室 First Department of Oral and Maxillofacial Surgery, School of Dentistry, Tsurumi University
    • 山村 秀夫 YAMAMURA Hideo
    • 日本歯科大学歯学部口腔外科学教室第一講座 The Nippon Dental University, School of Dentistry at Tokyo, Department of Oral and Maxillofacial Surgery 1

Abstract

We carried out a multicenter double-blind clinical study to evaluate the efficacy and usefulness of CS-670, a newly-developed nonsteroidal anti-inflammatory drug, in the treatment of pain in patients undergoing extraction of a mandibular impacted wisdom tooth. The following results were obtained:<BR>1) Three groups were compared. The CS20 group received 20 mg of CS-670, the CS40 group received 40 mg of CS-670, and LOX60 group received 60 mg of loxoprofen sodium as control.<BR>2) Eighty-six patients in the CS20 group, 85 in the CS40 group, and 80 in the LOX60 group were included in analyses.<BR>3) There were no significant differences in demographic factors or extraction conditions among the 3 groups.<BR>4) Based on the patient's impression, the improvement rates of cases assessed as “very effective” or “effective” were 71.6% in the CS20 group, 91.6% in the CS40 group, and 88.5% in the LOX60 group. The differences between the CS20 group and the latter 2 groups were significant.<BR>5) Based on the investigator's evaluation, the improvement rates of cases showing an “excellent” or “moderate” response were 67.9% in the CS20 group, 91.5% in the CS40 group, and 84.6% in the LOX60 group. The differences between the CS20 group and the latter 2 groups were significant.<BR>6) As adverse effects, drowsiness occurred in 3 patients (3.5%) in the CS20 group and 2 (2.4%) in the CS40 group. One patient (1.3%) in the LOX60 group complained of a feeling of sickness. However, all cases were evaluated to be unrelated to the study drugs.<BR>7) According to the criteria of the Evaluation Committee, excellent or good pain suppression was obtained in 48.1% of the CS20 group, 61.0% of the CS40 group, and 57.7% of the LOX60 group. The differences among the 3 groups were not significant. The onset of action was noted within one hour in 69.1% of the CS20 group, 82.9% of the CS40 group, and 83.3% of the LOX60 group. The difference between the CS20 group and the LOX60 group was significant. The duration of analgesic effect was more than 3 hours in 66.7% of the CS20 group, 92.6% of the CS40 group, and 82.1% of the LOX60 group. The differences between the CS20 group and the latter 2 groups were significant. The rates of excellent or good responses, evaluated based on the analgesic effect, the onset of action, and the duration of action, were 61.7% in the CS20 group, 76.5% in the CS40 group, and 80.8% in the LOX60 group. The difference between the former 2 groups was significant. Usefulness rates were 61.7% in the CS20 group, 72.3% in the CS40 group, and 80.8% in the LOX60 group. There were no significant differences among the 3 groups.<BR>These results demonstrate that the analgesic effect of 40 mg CS-670 is equal to or better than that of 60 mg loxoprofen sodium without inducing adverse effects. Thus, CS-670 is a very useful analgesic.

Journal

  • Japanese Journal of Oral and Maxillofacial Surgery

    Japanese Journal of Oral and Maxillofacial Surgery 41(3), 195-209, 1995-03-20

    Japanese Society of Oral and Maxillofacial Surgeons

References:  12

Codes

  • NII Article ID (NAID)
    10006610688
  • NII NACSIS-CAT ID (NCID)
    AN00189163
  • Text Lang
    JPN
  • Article Type
    ART
  • ISSN
    00215163
  • Data Source
    CJP  J-STAGE 
Page Top